Meredith Roath, MD
Gastroenterology · Huntsville, ALNPI 1497947949
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.7% of the total across 984 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 27.8% of the total. Among gastroenterology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 984 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$3K
- Johnson & Johnson$3K
- Takeda Pharmaceuticals U.S.A., Inc.$799
- Madrigal Pharmaceuticals$451
- Gilead$445
- plus $4K from 26 others
What the payments were for
- Food & beverage$15,77698%
- Education$2672%
- Gifts$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 236 | $4,481 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 300 | $3,499 |
| Johnson & Johnson | 152 | $2,624 |
| Takeda Pharmaceuticals U.S.A., Inc. | 49 | $799 |
| Madrigal Pharmaceuticals | 12 | $451 |
| Gilead | 21 | $445 |
| Regeneron Healthcare Solutions, Inc. | 20 | $434 |
| Merck | 22 | $385 |
| QOL Medical, LLC | 19 | $382 |
| Phathom Pharmaceuticals, Inc. | 16 | $370 |
| Ferring Pharmaceuticals Inc. | 20 | $351 |
| Ironwood Pharmaceuticals, Inc | 22 | $346 |
| Sanofi | 13 | $307 |
| Nestle Healthcare Nutrition Inc. | 25 | $264 |
| Intercept Pharmaceuticals, Inc. | 11 | $172 |
| Intra-sana Laboratories | 3 | $123 |
| Bristol Myers Squibb | 7 | $110 |
| UCB, Inc. | 7 | $93 |
| Redhill Biopharma Inc. | 5 | $91 |
| Lilly USA, LLC | 3 | $61 |
| Pfizer | 4 | $52 |
| Braintree Laboratories, Inc. | 3 | $50 |
| Aimmune Therapeutics, Inc. | 3 | $47 |
| Celltrion USA Inc. | 2 | $42 |
| Evoke Pharma, Inc. | 2 | $36 |
| Novo Nordisk | 1 | $24 |
| Biocompatibles, Inc. | 1 | $22 |
| EMD Serono, Inc. | 1 | $21 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Organon | 1 | $16 |
| Boston Scientific | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$241
- REZDIFFRA$146
- Mavyret$125
- STELARA$125
- Reltone 200 Mg$100
- Reltone 400 Mg$100
How this compares
$16,142 in reported general payments places this provider in the 90th percentile of 225 gastroenterology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 12 | $335,836 |
| CreonLipase/Protease/Amylase | 81 | $267,543 |
| LinzessLinaclotide | 125 | $94,948 |
| Humira(Cf) PenAdalimumab | 13 | $87,494 |
| XifaxanRifaximin | 21 | $66,009 |
| IbsrelaTenapanor Hcl | 35 | $64,194 |
| Dexlansoprazole DrDexlansoprazole | 35 | $12,227 |
| TrulancePlecanatide | 21 | $11,240 |
| AprisoMesalamine | 14 | $9,601 |
| Esomeprazole Magnesium | 94 | $9,245 |
| Lubiprostone | 53 | $8,633 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 132 | $8,322 |
| MovantikNaloxegol Oxalate | 12 | $6,394 |
| CholestyramineCholestyramine (With Sugar) | 56 | $6,320 |
| Colesevelam Hcl | 25 | $6,152 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $4,481 | $362,491206 claims |
| Johnson & JohnsonStelara | $2,624 | $335,83612 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance, Apriso | $3,499 | $86,84956 claims |
| Redhill Biopharma Inc.Movantik | $91 | $6,39412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 225 gastroenterology providers in Alabama.
Other gastroenterology in Huntsville
- John-Paul VoelkelHuntsville$17K
- Charles BillingsHuntsville$16K
- Dino FerranteHuntsville$15K
- Suresh KarneHuntsville$12K
- Rami HawariHuntsville$10K
- Prasad VankineniHuntsville$10K
- Eghierhua UgheokeHuntsville$10K
- Jason KinzelHuntsville$10K
- Keta VaidyaHuntsville$9K
- Michael DohrenwendHuntsville$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.